Stephen Archer to Cyclic Nucleotide Phosphodiesterases, Type 5
This is a "connection" page, showing publications Stephen Archer has written about Cyclic Nucleotide Phosphodiesterases, Type 5.
Connection Strength
0.298
-
The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014 Jun 20; 115(1):176-88.
Score: 0.121
-
Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. Drugs Aging. 2005; 22(10):823-44.
Score: 0.063
-
Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003 Oct 28; 108(17):2066-9.
Score: 0.058
-
Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia. Circulation. 2011 May 17; 123(19):2120-31.
Score: 0.024
-
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 Jul 17; 116(3):238-48.
Score: 0.019
-
Sildenafil reverses O2 constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. Pediatr Res. 2002 Jul; 52(1):19-24.
Score: 0.013